The next era of renal radionuclide imaging: novel PET radiotracers

Rudolf A. Werner, Xinyu Chen, Constantin Lapa, Kazuhiro Koshino, Steven P. Rowe, Martin G. Pomper, Mehrbod S. Javadi, Takahiro Higuchi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal radionuclide PET radiotracers, in particular focusing on novel 18F-labelled and 68Ga-labelled agents. Several reported PET imaging probes allow assessment of glomerular filtration rate, such as [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA), [68Ga]IRDye800-tilmanocept and 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS)). The diagnostic performance of [68Ga]EDTA has already been demonstrated in a clinical trial. [68Ga]IRDye800-tilmanocept shows receptor-mediated binding to glomerular mesangial cells, which in turn may allow the monitoring of progression of diabetic nephropathy. [18F]FDS shows excellent kidney extraction and excretion in rats and, as has been shown in the first study in humans. Further, due to its simple one-step radiosynthesis via the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-d-glucose, [18F]FDS could be available at nearly every PET centre. A new PET radiotracer has also been introduced for the effective assessment of plasma flow in the kidneys: Re(CO)3-N-([18F]fluoroethyl)iminodiacetic acid (Re(CO)3([18F]FEDA)). This compound demonstrates similar pharmacokinetic properties to its 99mTc-labelled analogue [99mTc](CO)3(FEDA). Thus, if there is a shortage of molybdenum-99, Re(CO)3([18F]FEDA would allow direct comparison with previous studies with 99mTc. The PET radiotracers for renal imaging reviewed here allow thorough evaluation of kidney function, with the tremendous advantage of precise anatomical coregistration with simultaneously acquired CT images and rapid three-dimensional imaging capability.

Original languageEnglish
Pages (from-to)1773-1786
Number of pages14
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume46
Issue number9
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Radionuclide Imaging
Positron-Emission Tomography
Kidney
Carbon Monoxide
Edetic Acid
Molecular Imaging
Mesangial Cells
Molybdenum
Three-Dimensional Imaging
Diabetic Nephropathies
Glomerular Filtration Rate
Photons
Radioisotopes
Pharmacokinetics
Clinical Trials
Glucose

Keywords

  • ERPF
  • GFR
  • Kidney
  • PET
  • Positron emission tomography
  • [F]Fluorodeoxysorbitol

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The next era of renal radionuclide imaging : novel PET radiotracers. / Werner, Rudolf A.; Chen, Xinyu; Lapa, Constantin; Koshino, Kazuhiro; Rowe, Steven P.; Pomper, Martin G.; Javadi, Mehrbod S.; Higuchi, Takahiro.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, No. 9, 01.08.2019, p. 1773-1786.

Research output: Contribution to journalReview article

Werner, Rudolf A. ; Chen, Xinyu ; Lapa, Constantin ; Koshino, Kazuhiro ; Rowe, Steven P. ; Pomper, Martin G. ; Javadi, Mehrbod S. ; Higuchi, Takahiro. / The next era of renal radionuclide imaging : novel PET radiotracers. In: European Journal of Nuclear Medicine and Molecular Imaging. 2019 ; Vol. 46, No. 9. pp. 1773-1786.
@article{46f6af0a835e4ed68d7408143eff1111,
title = "The next era of renal radionuclide imaging: novel PET radiotracers",
abstract = "Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal radionuclide PET radiotracers, in particular focusing on novel 18F-labelled and 68Ga-labelled agents. Several reported PET imaging probes allow assessment of glomerular filtration rate, such as [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA), [68Ga]IRDye800-tilmanocept and 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS)). The diagnostic performance of [68Ga]EDTA has already been demonstrated in a clinical trial. [68Ga]IRDye800-tilmanocept shows receptor-mediated binding to glomerular mesangial cells, which in turn may allow the monitoring of progression of diabetic nephropathy. [18F]FDS shows excellent kidney extraction and excretion in rats and, as has been shown in the first study in humans. Further, due to its simple one-step radiosynthesis via the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-d-glucose, [18F]FDS could be available at nearly every PET centre. A new PET radiotracer has also been introduced for the effective assessment of plasma flow in the kidneys: Re(CO)3-N-([18F]fluoroethyl)iminodiacetic acid (Re(CO)3([18F]FEDA)). This compound demonstrates similar pharmacokinetic properties to its 99mTc-labelled analogue [99mTc](CO)3(FEDA). Thus, if there is a shortage of molybdenum-99, Re(CO)3([18F]FEDA would allow direct comparison with previous studies with 99mTc. The PET radiotracers for renal imaging reviewed here allow thorough evaluation of kidney function, with the tremendous advantage of precise anatomical coregistration with simultaneously acquired CT images and rapid three-dimensional imaging capability.",
keywords = "ERPF, GFR, Kidney, PET, Positron emission tomography, [F]Fluorodeoxysorbitol",
author = "Werner, {Rudolf A.} and Xinyu Chen and Constantin Lapa and Kazuhiro Koshino and Rowe, {Steven P.} and Pomper, {Martin G.} and Javadi, {Mehrbod S.} and Takahiro Higuchi",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s00259-019-04359-8",
language = "English",
volume = "46",
pages = "1773--1786",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - The next era of renal radionuclide imaging

T2 - novel PET radiotracers

AU - Werner, Rudolf A.

AU - Chen, Xinyu

AU - Lapa, Constantin

AU - Koshino, Kazuhiro

AU - Rowe, Steven P.

AU - Pomper, Martin G.

AU - Javadi, Mehrbod S.

AU - Higuchi, Takahiro

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal radionuclide PET radiotracers, in particular focusing on novel 18F-labelled and 68Ga-labelled agents. Several reported PET imaging probes allow assessment of glomerular filtration rate, such as [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA), [68Ga]IRDye800-tilmanocept and 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS)). The diagnostic performance of [68Ga]EDTA has already been demonstrated in a clinical trial. [68Ga]IRDye800-tilmanocept shows receptor-mediated binding to glomerular mesangial cells, which in turn may allow the monitoring of progression of diabetic nephropathy. [18F]FDS shows excellent kidney extraction and excretion in rats and, as has been shown in the first study in humans. Further, due to its simple one-step radiosynthesis via the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-d-glucose, [18F]FDS could be available at nearly every PET centre. A new PET radiotracer has also been introduced for the effective assessment of plasma flow in the kidneys: Re(CO)3-N-([18F]fluoroethyl)iminodiacetic acid (Re(CO)3([18F]FEDA)). This compound demonstrates similar pharmacokinetic properties to its 99mTc-labelled analogue [99mTc](CO)3(FEDA). Thus, if there is a shortage of molybdenum-99, Re(CO)3([18F]FEDA would allow direct comparison with previous studies with 99mTc. The PET radiotracers for renal imaging reviewed here allow thorough evaluation of kidney function, with the tremendous advantage of precise anatomical coregistration with simultaneously acquired CT images and rapid three-dimensional imaging capability.

AB - Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal radionuclide PET radiotracers, in particular focusing on novel 18F-labelled and 68Ga-labelled agents. Several reported PET imaging probes allow assessment of glomerular filtration rate, such as [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA), [68Ga]IRDye800-tilmanocept and 2-deoxy-2-[18F]fluorosorbitol ([18F]FDS)). The diagnostic performance of [68Ga]EDTA has already been demonstrated in a clinical trial. [68Ga]IRDye800-tilmanocept shows receptor-mediated binding to glomerular mesangial cells, which in turn may allow the monitoring of progression of diabetic nephropathy. [18F]FDS shows excellent kidney extraction and excretion in rats and, as has been shown in the first study in humans. Further, due to its simple one-step radiosynthesis via the most frequently used PET radiotracer 2-deoxy-2-[18F]fluoro-d-glucose, [18F]FDS could be available at nearly every PET centre. A new PET radiotracer has also been introduced for the effective assessment of plasma flow in the kidneys: Re(CO)3-N-([18F]fluoroethyl)iminodiacetic acid (Re(CO)3([18F]FEDA)). This compound demonstrates similar pharmacokinetic properties to its 99mTc-labelled analogue [99mTc](CO)3(FEDA). Thus, if there is a shortage of molybdenum-99, Re(CO)3([18F]FEDA would allow direct comparison with previous studies with 99mTc. The PET radiotracers for renal imaging reviewed here allow thorough evaluation of kidney function, with the tremendous advantage of precise anatomical coregistration with simultaneously acquired CT images and rapid three-dimensional imaging capability.

KW - ERPF

KW - GFR

KW - Kidney

KW - PET

KW - Positron emission tomography

KW - [F]Fluorodeoxysorbitol

UR - http://www.scopus.com/inward/record.url?scp=85068697479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068697479&partnerID=8YFLogxK

U2 - 10.1007/s00259-019-04359-8

DO - 10.1007/s00259-019-04359-8

M3 - Review article

C2 - 31144061

AN - SCOPUS:85068697479

VL - 46

SP - 1773

EP - 1786

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 9

ER -